Latest period
$2.96B
YoY change
+30.6%
5Y CAGR
+8.5%
Peak year (2025)
$2.75B
Latest annual
$2.75B
Total Equity history chart for DexCom (DXCM) from 2000 to 2025
Latest: $2.75B
Total Equity growth chart for DexCom (DXCM) from 2000 to 2025
Latest: +30.6%
Total Equity history table for DexCom (DXCM) from 2000 to 2025
| 2025 | $2.75B | +30.6% | +$643.40M | ||
| 2024 | $2.10B | +1.6% | +$34.00M | ||
| 2023 | $2.07B | -3.0% | −$63.20M | ||
| 2022 | $2.13B | +4.4% | +$89.70M | ||
| 2021 | $2.04B | +11.8% | +$215.60M | ||
| 2020 | $1.83B | +106.9% | +$943.90M | ||
| 2019 | $882.60M | +33.1% | +$219.30M | ||
| 2018 | $663.30M | +58.2% | +$243.90M | ||
| 2017 | $419.40M | +47.8% | +$135.60M | ||
| 2016 | $283.80M | +28.3% | +$62.60M | ||
| 2015 | $221.20M | +57.8% | +$81.00M | ||
| 2014 | $140.20M | +66.7% | +$56.10M | ||
| 2013 | $84.10M | +9.2% | +$7.10M | ||
| 2012 | $77.00M | -26.3% | −$27.50M | ||
| 2011 | $104.50M | +71.3% | +$43.51M | ||
| 2010 | $60.99M | -430.7% | +$79.44M | ||
| 2009 | −$18.45M | -5.3% | +$1.02M | ||
| 2008 | −$19.47M | -373.6% | −$26.58M | ||
| 2007 | $7.12M | -87.5% | −$49.71M | ||
| 2006 | $56.83M | +15.0% | +$7.42M | ||
| 2005 | $49.41M | -200.2% | +$98.72M | ||
| 2004 | −$49.31M | +51.3% | −$16.71M | ||
| 2003 | −$32.60M | — | — | ||
| 2001 | −$8.93M | +179.8% | −$5.74M | ||
| 2000 | −$3.19M | — | — |
- 2025$2.75B+30.6%
- 2024$2.10B+1.6%
- 2023$2.07B-3.0%
- 2022$2.13B+4.4%
- 2021$2.04B+11.8%
- 2020$1.83B+106.9%
- 2019$882.60M+33.1%
- 2018$663.30M+58.2%
- 2017$419.40M+47.8%
- 2016$283.80M+28.3%
- 2015$221.20M+57.8%
- 2014$140.20M+66.7%
- 2013$84.10M+9.2%
- 2012$77.00M-26.3%
- 2011$104.50M+71.3%
- 2010$60.99M-430.7%
- 2009−$18.45M-5.3%
- 2008−$19.47M-373.6%
- 2007$7.12M-87.5%
- 2006$56.83M+15.0%
- 2005$49.41M-200.2%
- 2004−$49.31M+51.3%
- 2003−$32.60M—
- 2001−$8.93M+179.8%
- 2000−$3.19M—
Total Equity values are taken from DexCom's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at DexCom (DXCM)
According to DexCom's latest reported financial statements, the company's latest reported total equity is $2.96B. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, DexCom (DXCM) reported total equity of $2.75B – surged 30.6% year-over-year.
Over 2020–2025 (5 years), DexCom total equity expanded at a +8.5% compound annual rate, sustaining 2 straight years of year-over-year growth.
The record annual total equity stands at $2.75B, reached in 2025; the historical low of −$49.31M was recorded in 2004.
DexCom Total Equity by Year
DexCom Total Equity 2025: $2.75B
In 2025, DexCom reported total equity of $2.75B, surged 30.6% from 2024. This figure represents the highest annual value in the available history.
DexCom Total Equity 2024: $2.10B
DexCom total equity in 2024 was $2.10B, edged up 1.6% from 2023.
DexCom Total Equity 2023: $2.07B
2023's total equity for DexCom came in at $2.07B, edged down 3.0% below 2022.
DexCom Total Equity 2022: $2.13B
DexCom posted total equity of $2.13B in 2022, edged up 4.4% from 2021.
DexCom Total Equity 2021: $2.04B
DexCom total equity in 2021 was $2.04B.
See more financial history for DexCom (DXCM).
Sector peers by Total Equity
Healthcare peers of DexCom (DXCM), ranked by their latest total equity
| $94.11B | |
| $81.54B | |
| $52.61B | |
| $48.67B | |
| $30.52B | |
| $26.54B | |
| $8.66B | |
| −$3.27B |
- $94.11B
- $81.54B
- $52.61B
- $48.67B
- $30.52B
- $26.54B
- $8.66B
- −$3.27B
Frequently asked questions
DexCom (DXCM) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation